

Katherine R Tuttle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3465652/publications.pdf>

Version: 2024-02-01

203
papers

18,550
citations

25014

57
h-index

12933

131
g-index

213
all docs

213
docs citations

213
times ranked

17844
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, e65-e70.	0.5	5
2	Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 42-49.	2.2	12
3	Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 72-81.	1.0	6
4	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. <i>American Journal of Kidney Diseases</i> , 2022, 80, 132-138.	2.1	3
5	The authors reply:. <i>Kidney International</i> , 2022, 101, 420-421.	2.6	1
6	Nephron overload as a therapeutic target to maximize kidney lifespan. <i>Nature Reviews Nephrology</i> , 2022, 18, 171-183.	4.1	28
7	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 665-673.	3.0	4
8	Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation. <i>Kidney International</i> , 2022, 101, 1116-1125.	2.6	11
9	Changing the Trajectory of Heart Failure and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.00470122.	2.2	2
10	Post-acute COVID-19 syndrome and kidney diseases: what do we know?. <i>Journal of Nephrology</i> , 2022, 35, 795-805.	0.9	37
11	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. <i>Diabetes Care</i> , 2022, 45, 1445-1452.	4.3	18
12	Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 628-630.	2.2	2
13	Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108204.	1.2	15
14	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
15	Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260.	2.6	112
16	On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease. <i>Journal of Nephrology</i> , 2022, 35, 2191-2204.	0.9	12
17	Patient perspectives and involvement in precision medicine research. <i>Kidney International</i> , 2021, 99, 511-514.	2.6	5
18	Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. <i>Advances in Therapy</i> , 2021, 38, 180-200.	1.3	66

#	ARTICLE	IF	CITATIONS
19	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. <i>Nature Reviews Nephrology</i> , 2021, 17, 227-244.	4.1	87
20	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 385-394.	2.0	110
21	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 77, 94-109.	2.1	88
22	Rationale and design of the Kidney Precision Medicine Project. <i>Kidney International</i> , 2021, 99, 498-510.	2.6	94
23	SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 3-5.	5.5	2
24	Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis. <i>Kidney360</i> , 2021, 2, 254-262.	0.9	14
25	Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 660-668.	2.2	20
26	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. <i>Diabetes</i> , 2021, 70, 1-16.	0.3	53
27	Construct validity, ecological validity and acceptance of self-administered online neuropsychological assessment in adults. <i>Clinical Neuropsychologist</i> , 2021, 35, 148-164.	1.5	21
28	Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies. <i>Nephron</i> , 2021, 145, 245-255.	0.9	8
29	Therapeutic transformation for diabetic kidney disease. <i>Kidney International</i> , 2021, 99, 301-303.	2.6	5
30	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. <i>Pediatric Nephrology</i> , 2021, 36, 2747-2757.	0.9	3
31	GLP-1 Receptor Agonists in Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1578-1580.	2.2	11
32	Transforming the Care of Patients with Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1590-1600.	2.2	11
33	Racial-Ethnic Differences in Health-Related Quality of Life among Adults and Children with Glomerular Disease. <i>Glomerular Diseases</i> , 2021, 1, 105-117.	0.2	6
34	Breaking New Ground with Incretin Therapy in Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 560-561.	13.9	10
35	Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. <i>Kidney International Reports</i> , 2021, 6, 2575-2584.	0.4	15
36	Glycemic Variability and KIM-1-Induced Inflammation in the Diabetic Kidney. <i>Diabetes</i> , 2021, 70, 1617-1619.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 727-728.	5.5	1
38	Effects of caloric restriction and aerobic exercise on circulating cell-free mitochondrial DNA in patients with moderate-to-severe chronic kidney disease. <i>American Journal of Physiology - Renal Physiology</i> , 2021, , .	1.3	6
39	Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 318-327.	0.6	9
40	Autopopulus: A Novel Framework for Autoencoder Imputation on Large Clinical Datasets. , 2021, 2021, 2303-2309.		0
41	Clinician engagement in research as a path toward the learning health system: A regional survey across the northwestern United States. <i>Health Services Management Research</i> , 2020, 33, 33-42.	1.0	14
42	Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome. <i>Kidney International Reports</i> , 2020, 5, 414-425.	0.4	10
43	The landscape of diabetic kidney disease transformed. <i>Nature Reviews Nephrology</i> , 2020, 16, 67-68.	4.1	8
44	Medication use, renin-angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020, 21, 147032032094513.	1.0	2
45	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020, 142, e265-e286.	1.6	107
46	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	2.6	692
47	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. <i>Kidney International Reports</i> , 2020, 5, 1679-1689.	0.4	17
48	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	2.6	65
49	Supervised Exercise Intervention and Overall Activity in CKD. <i>Kidney International Reports</i> , 2020, 5, 1261-1270.	0.4	7
50	Impact of the COVID-19 pandemic on clinical research. <i>Nature Reviews Nephrology</i> , 2020, 16, 562-564.	4.1	94
51	Feasibility of connecting regional research programs to national multisite trials emanating from the CTSA Trial Innovation Network. <i>Journal of Clinical and Translational Science</i> , 2020, 4, 75-80.	0.3	0
52	We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury. <i>American Journal of Kidney Diseases</i> , 2020, 76, 454-456.	2.1	30
53	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 597-606.	1.4	14
54	The Authors Reply. <i>Kidney International Reports</i> , 2020, 5, 2405-2406.	0.4	0

#	ARTICLE	IF	CITATIONS
55	MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2
56	Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocrine Reviews, 2020, 41, 756-774.	8.9	77
57	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	13.9	228
58	TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	2
59	Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 444-446.	2.2	5
60	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International, 2020, 98, 839-848.	2.6	193
61	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.4	2
62	Evidence-based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. Diabetes, Obesity and Metabolism, 2020, 22, 1014-1023.	2.2	5
63	Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 285-288.	2.2	23
64	Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1375-1381.	1.1	10
65	Cardio-Renal-Metabolic Care Models. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007264.	0.9	25
66	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. US Endocrinology, 2020, 16, 80.	0.3	7
67	Inflammatory Mechanisms in Diabetic Kidney Disease. , 2020, , 437-455.		0
68	Annals On Call - The Good, the Bad, and the Ugly—the Sequel: GLP1 Agonists. Annals of Internal Medicine, 2020, 172, OC1.	2.0	0
69	Diabetic Kidney Disease. Nephrology Self-assessment Program: NephSAP, 2020, 19, 110-139.	3.0	1
70	Early Rapid Decline in Kidney Function in Medically Managed Patients With Atherosclerotic Renal Artery Stenosis. Journal of the American Heart Association, 2019, 8, e012366.	1.6	11
71	Sodium—Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes, 2019, 68, 248-257.	0.3	80
72	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol—Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	4.3	39

#	ARTICLE	IF	CITATIONS
73	SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 414-415.	5.5	0
74	Health-related quality of life in glomerular disease. <i>Kidney International</i> , 2019, 95, 1209-1224.	2.6	38
75	<p>Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study</p>. <i>International Journal of Nephrology and Renovascular Disease</i> , 2019, Volume 12, 49-58.	0.8	5
76	A turning point for chronic kidney disease in diabetes. <i>Lancet, The</i> , 2019, 393, 1913-1914.	6.3	2
77	Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial. <i>American Journal of Nephrology</i> , 2019, 49, 359-367.	1.4	6
78	Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease. <i>PLoS ONE</i> , 2019, 14, e0211555.	1.1	14
79	Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderateâ€toâ€severe chronic kidney disease (AWARDâ€7). <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1493-1497.	2.2	22
80	Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children. <i>JAMA Network Open</i> , 2019, 2, e1918169.	2.8	130
81	Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD. <i>BMC Nephrology</i> , 2019, 20, 416.	0.8	12
82	Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. <i>American Journal of Kidney Diseases</i> , 2019, 73, 372-384.	2.1	90
83	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. <i>American Journal of Kidney Diseases</i> , 2019, 73, 218-229.	2.1	68
84	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
85	Annals On Call - SGLT2 Inhibitors: The Good, the Bad, and the Ugly. <i>Annals of Internal Medicine</i> , 2019, 171, OC1.	2.0	0
86	Medication Therapy Management after Hospitalization in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 231-241.	2.2	29
87	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. <i>American Journal of Nephrology</i> , 2018, 47, 275-282.	1.4	31
88	Diabetic Kidney Disease (c. 2018). <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 119-120.	0.6	2
89	Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2018, 25, 181-191.	0.6	91
90	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1950-1959.	0.4	183

#	ARTICLE	IF	CITATIONS
91	Metabolic Effects of Diet and Exercise in Patients with Moderate to Severe CKD: A Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 250-259.	3.0	95
92	Disseminated Adenovirus Nephritis After Kidney Transplantation. <i>Kidney International Reports</i> , 2018, 3, 19-23.	0.4	13
93	GLP-1 receptor agonists, CKD, and eGFR trajectory – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 765.	5.5	0
94	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. <i>Kidney International Reports</i> , 2018, 3, 1373-1384.	0.4	39
95	Race in America. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 829-830.	2.2	0
96	Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2018, 48, 21-31.	1.4	42
97	GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1519-F1525.	1.3	31
98	Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 605-617.	5.5	392
99	SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 267-277.	2.1	102
100	Dietary strategies for cardiovascular health. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 295-313.	2.3	8
101	Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F716-F731.	1.3	184
102	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet</i> , 2017, 390, 1888-1917.	6.3	662
103	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2263-2274.	3.0	59
104	Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 2032-2045.	2.2	1,600
105	Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney. <i>Diabetes</i> , 2017, 66, 14-16.	0.3	68
106	Reducing major risk factors for chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 71-87.	4.6	155
107	Action plan for optimizing the design of clinical trials in chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 138-144.	4.6	19
108	Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes. <i>American Journal of Nephrology</i> , 2017, 46, 276-284.	1.4	11

#	ARTICLE	IF	CITATIONS
109	Diabetes and CKD in the United States Population, 2009–2014. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1984-1990.	2.2	117
110	The Northwest Participant and Clinical Interactions Network: Increasing opportunities for patients to participate in research across the Northwestern United States. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 94-100.	0.3	4
111	Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 436-441.	2.2	54
112	Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis. <i>PLoS ONE</i> , 2017, 12, e0173562.	1.1	11
113	Connecting Patients to Prescription Assistance Programs: Effects on Emergency Department and Hospital Utilization. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 381-387.	0.5	11
114	Preserving Self: Medication-Taking Practices and Preferences of Older Adults With Multiple Chronic Medical Conditions. <i>Journal of Nursing Scholarship</i> , 2016, 48, 533-542.	1.1	9
115	Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1180-1188.	2.2	25
116	Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 602.	3.8	669
117	Serum amyloid A and risk of death and end-stage renal disease in diabetic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1467-1472.	1.2	23
118	Relationship of Albuminuria and Renal Artery Stent Outcomes. <i>Hypertension</i> , 2016, 68, 1145-1152.	1.3	50
119	Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2016, 44, 122-129.	1.4	10
120	Association Between Prescription Opioid Use and Biomarkers of Kidney Disease in US Adults. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 365-373.	0.9	13
121	JAK inhibition in the treatment of diabetic kidney disease. <i>Diabetologia</i> , 2016, 59, 1624-1627.	2.9	107
122	Complete Remission in the Nephrotic Syndrome Study Network. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 81-89.	2.2	53
123	The Surging Tide of Diabetes: Implications for Nephrology. <i>American Journal of Kidney Diseases</i> , 2016, 67, 364-366.	2.1	3
124	Renal Artery Stent Outcomes. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2487-2494.	1.2	40
125	Effect of Ruboxistaurin on Albuminuria and Estimated GFR in People With Diabetic Peripheral Neuropathy: Results From a Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 634-636.	2.1	22
126	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. <i>Diabetes Spectrum</i> , 2015, 28, 167-174.	0.4	18

#	ARTICLE	IF	CITATIONS
127	Diabetic Kidney Disease: A Call to Action: Preface. <i>Diabetes Spectrum</i> , 2015, 28, 158-160.	0.4	1
128	Serum amyloid A and inflammation in diabetic kidney disease and podocytes. <i>Laboratory Investigation</i> , 2015, 95, 250-262.	1.7	64
129	Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine. <i>Annals of Pharmacotherapy</i> , 2014, 48, 571-576.	0.9	22
130	Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. <i>New England Journal of Medicine</i> , 2014, 370, 13-22.	13.9	804
131	Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease. <i>Physiological Reports</i> , 2014, 2, e12010.	0.7	13
132	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>American Journal of Kidney Diseases</i> , 2014, 64, 510-533.	2.1	439
133	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>Diabetes Care</i> , 2014, 37, 2864-2883.	4.3	781
134	Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1199-1206.	2.2	28
135	Novel Therapies for Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 121-133.	0.6	55
136	Association of Co-Occurring Serious Mental Illness with Emergency Hospitalization in People with Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2014, 39, 260-267.	1.4	14
137	Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2013, 62, 396-398.	2.1	24
138	New Therapies for Diabetic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2549-2550.	13.9	75
139	Glomerular cell death and inflammation with high-protein diet and diabetes. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1711-1720.	0.4	38
140	Direct and Indirect Effects of Obesity on the Kidney. <i>Advances in Chronic Kidney Disease</i> , 2013, 20, 121-127.	0.6	32
141	Type 2 Translational Research for CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1829-1838.	2.2	13
142	Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 302-308.	3.0	862
143	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. <i>Kidney International</i> , 2013, 83, 749-756.	2.6	268
144	Classification of Chronic Kidney Disease Biomarkers to Predict Coronary Artery Calcium. <i>Kidney and Blood Pressure Research</i> , 2012, 36, 26-35.	0.9	3

#	ARTICLE	IF	CITATIONS
145	Risks of Subsequent Hospitalization and Death in Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 409-416.	2.2	78
146	Co-occurring mood disorders among hospitalized patients and risk for subsequent medical hospitalization. <i>General Hospital Psychiatry</i> , 2012, 34, 500-505.	1.2	23
147	Dietary Amino Acids and Blood Pressure: A Cohort Study of Patients With Cardiovascular Disease. <i>American Journal of Kidney Diseases</i> , 2012, 59, 803-809.	2.1	59
148	Dietary Paradoxes to Optimize Cardiovascular Risk Management in Chronic Kidney Disease. , 2012, , 213-237.		0
149	Meta-Analysis Comparing Mediterranean to Low-Fat Diets for Modification of Cardiovascular Risk Factors. <i>American Journal of Medicine</i> , 2011, 124, 841-851.e2.	0.6	253
150	Modulation of Advanced Glycation End Products by Candesartan in Patients with Diabetic Kidney Disease-A Dose-Response Relationship Study. <i>American Journal of Therapeutics</i> , 2010, 17, 553-558.	0.5	13
151	Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors. <i>American Journal of Kidney Diseases</i> , 2010, 55, 426-430.	2.1	34
152	Management of the Diabetic Patient with Advanced Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2010, 23, 140-147.	0.7	20
153	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1
154	Charting New Territory by Simulated Modeling of a Clinical Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 750-752.	2.2	2
155	Influence of Glycemic Control on the Development of Diabetic Cardiovascular and Kidney Disease. <i>Cardiology Clinics</i> , 2010, 28, 497-516.	0.9	6
156	The "Eco-Atkins" Diet. <i>Archives of Internal Medicine</i> , 2009, 169, 1027.	4.3	3
157	Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2009, 5, 20-21.	2.9	1
158	Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1968-1973.	2.2	91
159	Obesity Management in Adults With CKD. <i>American Journal of Kidney Diseases</i> , 2009, 53, 151-165.	2.1	41
160	More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2009, 53, 12-15.	2.1	2
161	Should albuminuria be a focus of antihypertensive therapy goals?. <i>Current Hypertension Reports</i> , 2009, 11, 354-362.	1.5	1
162	Oxidative Stress Mediates Protein Kinase C Activation and Advanced Glycation End Product Formation in a Mesangial Cell Model of Diabetes and High Protein Diet. <i>American Journal of Nephrology</i> , 2009, 29, 171-180.	1.4	34

#	ARTICLE	IF	CITATIONS
163	Can Comprehensive Lifestyle Change Alter the Course of Chronic Kidney Disease?. Seminars in Nephrology, 2009, 29, 512-523.	0.6	13
164	Comparison of Low-Fat Versus Mediterranean-Style Dietary Intervention After First Myocardial Infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial)â€œConflicts of interest: Dr. Bibus has received consulting fees from companies that make fish oil, Coromega Co., Vista, CA, and Enreco, Inc., Newton, WI. He also has equity ownership in Lipid Technologies, LLC, Austin, MN, the company that performed the plasma fatty acid analysis. Dr. Bibus owns patents related to lipid therapy. H. American Journal of Cardiology, 2008, 101, 1523-1530.	0.7	109
165	Protein kinase C- β 2 inhibition for diabetic kidney disease. Diabetes Research and Clinical Practice, 2008, 82, S70-S74.	1.1	34
166	Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury?. Current Opinion in Nephrology and Hypertension, 2008, 17, 443-449.	1.0	21
167	Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 631-636.	2.2	87
168	Effect of Ruboxistaurin on Urinary Transforming Growth Factor- β 1 in Patients With Diabetic Nephropathy and Type 2 Diabetes. Diabetes Care, 2007, 30, 995-996.	4.3	50
169	Protein kinase C β 2 inhibition: the promise for treatment of diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2007, 16, 397-402.	1.0	18
170	The New KDOQI TM Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and CKD. Blood Purification, 2007, 25, 112-114.	0.9	48
171	Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. Current Hypertension Reports, 2007, 9, 393-402.	1.5	8
172	A causal role for uric acid in fructose-induced metabolic syndrome. American Journal of Physiology - Renal Physiology, 2006, 290, F625-F631.	1.3	889
173	Implications of Chronic Kidney Disease for Dietary Treatment in Cardiovascular Disease. , 2006, 16, 259-268.		20
174	Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1293-1299.	2.2	75
175	Major Risks Indicators for Diabetic Kidney Disease. , 2006, , 351-357.		0
176	Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney International, 2005, 67, 953-968.	2.6	34
177	The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. Diabetes Care, 2005, 28, 2686-2690.	4.3	283
178	Linking Metabolism and Immunology: Diabetic Nephropathy Is an Inflammatory Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 1537-1538.	3.0	184
179	Uric Acid, Microalbuminuria and Cardiovascular Events in High-Risk Patients. American Journal of Nephrology, 2005, 25, 36-44.	1.4	45
180	Renal manifestations of the metabolic syndrome. Nephrology Dialysis Transplantation, 2005, 20, 861-864.	0.4	24

#	ARTICLE	IF	CITATIONS
181	Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: A statistical modeling perspective. <i>Seminars in Nephrology</i> , 2005, 25, 25-31.	0.6	30
182	The next generation of diabetic nephropathy therapies: An update. <i>Advances in Chronic Kidney Disease</i> , 2005, 12, 212-222.	0.6	26
183	Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 80-86.	2.0	293
184	Cardiovascular Implications of Albuminuria. <i>Journal of Clinical Hypertension</i> , 2004, 6, 13-17.	1.0	16
185	Atherosclerotic renal artery stenosis: current status and future directions. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 613-621.	1.0	17
186	Predictors of ARF after cardiac surgical procedures. <i>American Journal of Kidney Diseases</i> , 2003, 41, 76-83.	2.1	201
187	A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C $\hat{2}$ inhibition. <i>American Journal of Kidney Diseases</i> , 2003, 42, 456-465.	2.1	85
188	Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?. <i>Hypertension</i> , 2003, 41, 1183-1190.	1.3	1,121
189	Amino acids induce indicators of response to injury in glomerular mesangial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2003, 285, F79-F86.	1.3	21
190	Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, F103-F112.	1.3	36
191	Renal parenchymal injury as a determinant of clinical consequences in atherosclerotic renal artery stenosis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 1321-1322.	2.1	14
192	Effects of amino acids and glucose on mesangial cell aminopeptidase a and angiotensin receptors. <i>Kidney International</i> , 2002, 61, S106-S109.	2.6	14
193	Ischemic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 167-173.	1.0	15
194	Sex differences in uric acid and risk factors for coronary artery disease. <i>American Journal of Cardiology</i> , 2001, 87, 1411-1414.	0.7	146
195	Much Ado About Nothing, or Much to Do About Something? The Continuing Controversy Over the Role of Uric Acid in Cardiovascular Disease. <i>Hypertension</i> , 2000, 35, E10.	1.3	37
196	Preserving renal function in adults with hypertension and diabetes: A consensus approach. <i>American Journal of Kidney Diseases</i> , 2000, 36, 646-661.	2.1	1,314
197	Toward more rational management of ischemic nephropathy: The need for clinical evidence. <i>American Journal of Kidney Diseases</i> , 2000, 36, 863-865.	2.1	11
198	Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. <i>American Journal of Kidney Diseases</i> , 1999, 34, 918-925.	2.1	71

#	ARTICLE	IF	CITATIONS
199	Endovascular stents for renal artery revascularization. <i>Current Opinion in Nephrology and Hypertension</i> , 1998, 7, 695-702.	1.0	13
200	Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes. <i>Metabolism: Clinical and Experimental</i> , 1992, 41, 116-120.	1.5	87
201	Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. <i>Kidney International</i> , 1992, 42, 167-173.	2.6	36
202	Effect of Strict Glycemic Control on Renal Hemodynamic Response to Amino Acids and Renal Enlargement in Insulin-Dependent Diabetes Mellitus. <i>New England Journal of Medicine</i> , 1991, 324, 1626-1632.	13.9	195
203	A perspective on nonsteroidal mineralocorticoid receptor antagonism in diabetic kidney disease. <i>Kidney360</i> , 0, , 10.34067/KID.0007072021.	0.9	0